FY2026 EPS Estimates for Penumbra Reduced by Leerink Partnrs

Key Points

• Leerink Partners has reduced its FY2026 earnings estimates for Penumbra, Inc., anticipating earnings of $5.38 per share, down from a previous forecast of $5.69.
• Despite the downgrade, Penumbra reported strong quarterly earnings of $0.86 EPS, exceeding analysts' expectations of $0.81 and showing a 13.4% year-over-year revenue increase.
• The stock has been rated with an average of "Moderate Buy" based on analyst ratings, with a consensus price target of $302.81.

Penumbra, Inc. (NYSE:PEN - Free Report) - Investment analysts at Leerink Partnrs cut their FY2026 earnings estimates for Penumbra in a research report issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now expects that the company will earn $5.38 per share for the year, down from their prior forecast of $5.69. The consensus estimate for Penumbra's current full-year earnings is $3.67 per share. Leerink Partnrs also issued estimates for Penumbra's FY2027 earnings at $7.09 EPS, FY2028 earnings at $8.49 EPS and FY2029 earnings at $9.61 EPS.

Penumbra (NYSE:PEN - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.05. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The company had revenue of $339.46 million for the quarter, compared to analysts' expectations of $327.37 million. During the same quarter last year, the company posted $0.64 earnings per share. The firm's quarterly revenue was up 13.4% on a year-over-year basis. Penumbra has set its FY 2025 guidance at EPS.

A number of other analysts also recently issued reports on the stock. William Blair upgraded shares of Penumbra to a "strong-buy" rating in a report on Friday, July 18th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Penumbra in a research note on Wednesday, October 8th. Wells Fargo & Company set a $290.00 price objective on shares of Penumbra in a research report on Wednesday, October 1st. Canaccord Genuity Group set a $350.00 price target on shares of Penumbra and gave the company a "buy" rating in a report on Wednesday, July 30th. Finally, UBS Group set a $335.00 price target on shares of Penumbra and gave the company a "buy" rating in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $302.81.

Penumbra Stock Down 0.9%

Shares of PEN stock opened at $252.70 on Thursday. The company has a market capitalization of $9.86 billion, a price-to-earnings ratio of 67.21, a PEG ratio of 2.30 and a beta of 0.41. Penumbra has a one year low of $198.68 and a one year high of $310.00. The company's fifty day moving average price is $260.04 and its 200-day moving average price is $261.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 4.04.

Insider Buying and Selling at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 186 shares of Penumbra stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $248.61, for a total transaction of $46,241.46. Following the completion of the sale, the director directly owned 8,702 shares in the company, valued at $2,163,404.22. This trade represents a 2.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arani Bose sold 12,000 shares of Penumbra stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $250.65, for a total transaction of $3,007,800.00. Following the completion of the transaction, the director owned 558 shares of the company's stock, valued at $139,862.70. This trade represents a 95.56% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 80,610 shares of company stock valued at $20,088,148. 4.20% of the stock is currently owned by company insiders.

Institutional Trading of Penumbra

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC purchased a new stake in shares of Penumbra during the first quarter worth about $259,000. GAMMA Investing LLC increased its holdings in Penumbra by 59.0% during the 1st quarter. GAMMA Investing LLC now owns 709 shares of the company's stock worth $190,000 after purchasing an additional 263 shares during the last quarter. Fortis Capital Advisors LLC acquired a new stake in Penumbra in the first quarter valued at $732,000. Belpointe Asset Management LLC acquired a new stake in shares of Penumbra during the first quarter worth $732,000. Finally, Sheets Smith Investment Management bought a new stake in shares of Penumbra during the first quarter valued at approximately $773,000. Institutional investors and hedge funds own 88.88% of the company's stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.